The Company enters into two types of licensing agreements and in both types, the Company earns revenue on the initial license fees. Under the technology agreements, the Company earns processing and storage royalties from the affiliates that process in their own facility. Under the marketing agreements, the Company earns processing and storage revenues from affiliates that store specimens in the Company’s facility in Oldsmar, Florida.

The Company has entered into a definitive License and Royalty Agreement with LifeCell International Private Limited, formerly Asia Cryo-Cell Private Limited, (“LifeCell”) to establish and market its umbilical cord blood and menstrual stem cell programs in India.

Per the License and Royalty Agreement with Lifecell, there is a $

cap on the amount of royalty due to the Company per year and a $

cap on the amount of royalties due to the Company for the term of the License and Royalty Agreement. 

Since inception of the License and Royalty Agreement, the Company has recorded approximately $

in royalty income due under the terms of the License and Royalty Agreement, of which, Lifecell has paid the Company approximately $

as of August 31, 2019. The balance of approximately $

is reflected as Accounts Receivable on the accompanying consolidated balance sheets.

The Company has definitive license agreements to market the Company’s umbilical cord blood stem cell programs in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panama and Pakistan.    

The following table details the initial license fees for the technology agreements and processing and storage royalties earned under the technology agreements for the three and nine months ended August 31, 2019 and August 31, 2018. The initial license fees and processing and storage royalties are reflected in licensee and royalty income in the accompanying consolidated statements of comprehensive income (loss).